| 000 | 01820 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517163827.0 | ||
| 264 | 0 | _c20171005 | |
| 008 | 201710s 0 0 eng d | ||
| 022 | _a1880-3989 | ||
| 024 | 7 |
_a10.2131/jts.42.427 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKawamoto, Taisuke | |
| 245 | 0 | 0 |
_aMechanism-based risk assessment strategy for drug-induced cholestasis using the transcriptional benchmark dose derived by toxicogenomics. _h[electronic resource] |
| 260 |
_bThe Journal of toxicological sciences _c2017 |
||
| 300 |
_a427-436 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aChlorpromazine _xadministration & dosage |
| 650 | 0 | 4 |
_aCholestasis _xchemically induced |
| 650 | 0 | 4 |
_aCholesterol _xbiosynthesis |
| 650 | 0 | 4 |
_aCyclosporine _xadministration & dosage |
| 650 | 0 | 4 |
_aDiclofenac _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aFlutamide _xadministration & dosage |
| 650 | 0 | 4 | _aGene Expression |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImipramine _xadministration & dosage |
| 650 | 0 | 4 |
_aInflammation _xgenetics |
| 650 | 0 | 4 |
_aKetoconazole _xadministration & dosage |
| 650 | 0 | 4 | _aLiver |
| 650 | 0 | 4 |
_aMethyltestosterone _xadministration & dosage |
| 650 | 0 | 4 |
_aOxidative Stress _xgenetics |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 |
_aRisk Assessment _xmethods |
| 650 | 0 | 4 |
_aSulindac _xadministration & dosage |
| 650 | 0 | 4 |
_aTamoxifen _xadministration & dosage |
| 650 | 0 | 4 |
_aToxicogenetics _xmethods |
| 700 | 1 | _aIto, Yuichi | |
| 700 | 1 | _aMorita, Osamu | |
| 700 | 1 | _aHonda, Hiroshi | |
| 773 | 0 |
_tThe Journal of toxicological sciences _gvol. 42 _gno. 4 _gp. 427-436 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2131/jts.42.427 _zAvailable from publisher's website |
| 999 |
_c27376913 _d27376913 |
||